Muraglitazar是一种PPARα/γ双重激动剂，具有研究2型糖尿病及相关血脂异常的潜力。Muraglitazar 对PPARα和PPARγ的EC₅₀分别为320 nM和110 nM，能够调节血糖和血脂代谢，适用于糖尿病和代谢综合征的研究。

Anti-NASH agent 1是Elafibranor的衍生物，作为强效的PPAR-α/δ激动剂，靶向非酒精性脂肪性肝炎 (NASH)。它在剂量为3-10 mg/kg，持续4周的实验中，能改善甲硫氨酸胆碱缺乏 (MCD) 诱导的NASH小鼠模型的高脂血症、肝脂肪变性和肝炎，具有低肝毒性和显著的肝保护作用。

AMG-131 is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.

4-O-Methyl honokiol is a natural neolignan isolated from magnolia officinalis which acts as a PPARγ agonist and inhibtis NF-κB activity. It is used for cancer and inflammation research.

PD184161 is an orally-active MEK inhibitor with antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity.

4-(4-Hydroxyphenyl)-2-butanone is the primary aroma compound of red raspberries and shows PPAR-α agonistic activity.

CRX000227是一种 PPAR 调节剂，适用于代谢性疾病或与细胞增殖相关疾病的研究。

SR 16832是一种双位点共价 PPARγ 抑制剂，能够同时作用于正构位点和变构位点，具有潜在的代谢和炎症相关疾病治疗应用。

GQ-16是 PPARγ 的中等亲和力配体，Ki 值为 160 nM，能够有效抑制 Cdk5 介导的 PPARγ 磷酸化。此外，GQ-16 作为 PPARγ 的部分激动剂，减少脂肪生成，并能促进胰岛素敏感性而不增加体重。

FH535是一种Wnt/β-catenin和PPAR的抑制剂，具有抗肿瘤活性。

Netoglitazone是一种 PPARα 和 PPARγ 的双重激动剂，具有显著的降血糖活性，适用于 2 型糖尿病及其相关代谢紊乱的研究，能够调节血糖和脂质代谢。

LY518674是一种高效、选择性的 PPARα 激动剂，EC₅₀ 为 42 nM，能够降低甘油三酸酯并增加 HDL-C，广泛用于动脉粥样硬化及代谢性疾病的研究。

FX-909是一种共价的过氧化物酶体增殖体激活受体γ (PPARG) 逆激动剂，用于肿瘤研究。

Indeglitazar是一种具有口服活性的 PPAR 泛激动剂，能够激活 PPARα、PPARδ 和 PPARγ，适用于糖尿病、代谢综合征以及脂质代谢紊乱相关疾病的研究。

Palmitelaidic Acid (9-trans-Hexadecenoic acid) 是反式异构体的棕榈油酸。棕榈油酸是血清和组织中最丰富的脂肪酸之一。

SR 202 is a selective PPARγ antagonist which attenuates troglitazone-induced PPARγ transcriptional activity with IC50 value of 140μM. It inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo and improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.

Pemafibrateis a selective PPARα modulator (SPPARMα) that has antihyperlipidaemic activity.

BMS-687453 is a potent and selective PPARα agonist, with an EC50 of 10 nM for human PPARα and 410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.

Elafibranor is an agonist of PPARα and PPARδ with EC50 values of 45 nM and 175 nM, respectively. Elafibranor also attenuates nonalcoholic steatohepatitis without fibrosis worsening.

Balaglitazone is a partial agonist of PPAR-γ.